Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MBRX NASDAQ:MIRA NASDAQ:MTVA NASDAQ:NLSP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBRXMoleculin Biotech$0.51+5.7%$0.48$0.25▼$3.65$23.88M1.592.59 million shs2.42 million shsMIRAMIRA Pharmaceuticals$1.62-10.0%$1.39$0.73▼$2.56$34.33M1.698.28 million shs5.55 million shsMTVAMetaVia$0.97-6.5%$0.85$0.56▼$3.16$25.17M0.37199,500 shs70,680 shsNLSPNLS Pharmaceutics$1.65+1.2%$2.12$1.30▼$5.64$5.86M0.14901,888 shs70,767 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBRXMoleculin Biotech-5.41%-6.53%+28.81%-39.85%-80.23%MIRAMIRA Pharmaceuticals+36.36%+34.33%+37.40%0.00%+63.64%MTVAMetaVia-4.59%+0.97%-21.80%+54.33%+103,999,900.00%NLSPNLS Pharmaceutics-4.12%-12.83%-23.11%-26.58%-67.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBRXMoleculin Biotech$0.51+5.7%$0.48$0.25▼$3.65$23.88M1.592.59 million shs2.42 million shsMIRAMIRA Pharmaceuticals$1.62-10.0%$1.39$0.73▼$2.56$34.33M1.698.28 million shs5.55 million shsMTVAMetaVia$0.97-6.5%$0.85$0.56▼$3.16$25.17M0.37199,500 shs70,680 shsNLSPNLS Pharmaceutics$1.65+1.2%$2.12$1.30▼$5.64$5.86M0.14901,888 shs70,767 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBRXMoleculin Biotech-5.41%-6.53%+28.81%-39.85%-80.23%MIRAMIRA Pharmaceuticals+36.36%+34.33%+37.40%0.00%+63.64%MTVAMetaVia-4.59%+0.97%-21.80%+54.33%+103,999,900.00%NLSPNLS Pharmaceutics-4.12%-12.83%-23.11%-26.58%-67.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBRXMoleculin Biotech 2.33Hold$4.00684.31% UpsideMIRAMIRA Pharmaceuticals 1.00SellN/AN/AMTVAMetaVia 2.33Hold$7.50671.05% UpsideNLSPNLS Pharmaceutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest NLSP, MIRA, MTVA, and MBRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025NLSPNLS PharmaceuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MBRXMoleculin BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MIRAMIRA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MTVAMetaViaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MBRXMoleculin BiotechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MIRAMIRA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025MTVAMetaViaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NLSPNLS PharmaceuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/10/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.009/4/2025MTVAMetaViaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.008/27/2025MBRXMoleculin BiotechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBRXMoleculin BiotechN/AN/AN/AN/A$1.77 per shareN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/A$0.13 per shareN/AMTVAMetaViaN/AN/AN/AN/A$0.92 per shareN/ANLSPNLS PharmaceuticsN/AN/AN/AN/A($0.37) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBRXMoleculin Biotech-$21.76MN/A0.00N/AN/AN/A-1,498.41%-114.47%11/14/2025 (Estimated)MIRAMIRA Pharmaceuticals-$7.85M-$0.490.00N/AN/AN/A-406.70%-328.44%11/11/2025 (Estimated)MTVAMetaVia-$27.59MN/A0.00N/AN/AN/A-212.00%-107.21%11/6/2025 (Estimated)NLSPNLS Pharmaceutics-$1.98MN/A0.00∞N/AN/AN/AN/AN/ALatest NLSP, MIRA, MTVA, and MBRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025MBRXMoleculin Biotech-$0.20N/AN/AN/AN/AN/A11/11/2025N/AMIRAMIRA Pharmaceuticals-$0.11N/AN/AN/AN/AN/A11/6/2025Q3 2025MTVAMetaVia-$0.26N/AN/AN/AN/AN/A8/14/2025Q2 2025MIRAMIRA Pharmaceuticals-$0.11-$0.09+$0.02-$0.09N/AN/A8/12/2025Q2 2025MBRXMoleculin Biotech-$0.39-$0.49-$0.10-$0.49N/AN/A8/7/2025Q2 2025MTVAMetaVia-$0.32-$0.26+$0.06-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMBRXMoleculin BiotechN/AN/AN/AN/AN/AMIRAMIRA PharmaceuticalsN/AN/AN/AN/AN/AMTVAMetaViaN/AN/AN/AN/AN/ANLSPNLS PharmaceuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBRXMoleculin BiotechN/A1.151.15MIRAMIRA PharmaceuticalsN/A2.802.80MTVAMetaViaN/A2.082.08NLSPNLS PharmaceuticsN/A2.77N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBRXMoleculin Biotech15.52%MIRAMIRA Pharmaceuticals35.16%MTVAMetaVia1.37%NLSPNLS PharmaceuticsN/AInsider OwnershipCompanyInsider OwnershipMBRXMoleculin Biotech3.40%MIRAMIRA Pharmaceuticals6.65%MTVAMetaVia0.80%NLSPNLS Pharmaceutics16.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBRXMoleculin Biotech2049.50 million47.82 millionNot OptionableMIRAMIRA Pharmaceuticals219.07 million17.80 millionNot OptionableMTVAMetaVia824.20 million24.00 millionN/ANLSPNLS Pharmaceutics63.60 million3.01 millionNot OptionableNLSP, MIRA, MTVA, and MBRX HeadlinesRecent News About These CompaniesNLS Pharmaceutics' (NLSP) Sell (E+) Rating Reiterated at Weiss RatingsOctober 17 at 2:55 AM | americanbankingnews.comWall Street Zen Downgrades NLS Pharmaceutics (NASDAQ:NLSP) to SellOctober 7, 2025 | americanbankingnews.comNLS Pharmaceutics stock tumbles after merger approval with KadimastemSeptember 30, 2025 | za.investing.comNLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General MeetingSeptember 30, 2025 | prnewswire.comNLS Pharmaceutics files to sell 5M common shares for holdersSeptember 25, 2025 | msn.comNLS Pharmaceutics Engages New Accounting Firm After Marcum’s ResignationSeptember 19, 2025 | tipranks.comKadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed MergerSeptember 10, 2025 | prnewswire.comNLS Pharmaceutics and Kadimastem Secure Hong Kong Patent for Diabetes TherapySeptember 4, 2025 | msn.comNLS Pharmaceutics and Kadimastem granted patent in Hong Kong for diabetesSeptember 4, 2025 | msn.comNLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes PatientsSeptember 4, 2025 | prnewswire.comNLS Pharmaceutics Reschedules Shareholders’ Meeting Amid SEC ReviewAugust 25, 2025 | msn.comNLS Pharmaceutics Enters Warrant Exchange Agreement with Alpha CapitalAugust 14, 2025 | theglobeandmail.comNLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell TherapyJuly 17, 2025 | prnewswire.comNLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity FinancingJune 30, 2025 | prnewswire.comNLS Pharmaceutics Ltd.: NLS Pharmaceutics CEO Issues Letter to ShareholdersJune 18, 2025 | finanznachrichten.deNLS Pharmaceutics CEO Issues Letter to ShareholdersJune 16, 2025 | prnewswire.comNLS Pharmaceutics to present Mazindol study at ASCP MeetingMay 22, 2025 | investing.comNLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual MeetingMay 21, 2025 | prnewswire.comNLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal ModelsApril 15, 2025 | prnewswire.comNLS Pharmaceutics, Kadimastem announce up to $3M equity financingApril 1, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNLSP, MIRA, MTVA, and MBRX Company DescriptionsMoleculin Biotech NASDAQ:MBRX$0.51 +0.03 (+5.72%) Closing price 04:00 PM EasternExtended Trading$0.51 0.00 (-0.59%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.MIRA Pharmaceuticals NASDAQ:MIRA$1.62 -0.18 (-10.00%) Closing price 04:00 PM EasternExtended Trading$1.60 -0.02 (-0.93%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.MetaVia NASDAQ:MTVA$0.97 -0.07 (-6.47%) As of 04:00 PM EasternMetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.NLS Pharmaceutics NASDAQ:NLSP$1.65 +0.02 (+1.23%) Closing price 04:00 PM EasternExtended Trading$1.65 0.00 (0.00%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
